Last reviewed · How we verify
CST-3056
CST-3056 is a small molecule inhibitor of the CDK9 enzyme.
CST-3056 is a small molecule inhibitor of the CDK9 enzyme. Used for Relapsed or refractory T-cell lymphoma.
At a glance
| Generic name | CST-3056 |
|---|---|
| Sponsor | CuraSen Therapeutics, Inc. |
| Drug class | CDK9 inhibitor |
| Target | CDK9 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
CDK9 inhibition is a strategy to block the transcriptional elongation factor P-TEFb, which is involved in the regulation of gene expression. By inhibiting CDK9, CST-3056 aims to modulate the expression of genes involved in various diseases.
Approved indications
- Relapsed or refractory T-cell lymphoma
Common side effects
- Fatigue
- Nausea
- Diarrhea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CST-3056 CI brief — competitive landscape report
- CST-3056 updates RSS · CI watch RSS
- CuraSen Therapeutics, Inc. portfolio CI